@wheezemd

Allergist, Executive Medical Director of the American College of Allergy, Asthma, and Immunology

 iPhone
Joined February 2008
  • Tweets15.6K
  • Following830
  • Followers3.8K
71Media
Michael Blaiss, MD retweeted
Peter Mallouk
@PeterMallouk6 Oct 2023
The average US family health insurance premium has increased from $6,000 in 2000 to $21,000 in 2022. That’s a 249% increase, or 5.8% per year, more than double inflation. The biggest beneficiaries of this massive increase in costs: health insurance companies. UnitedHealth (largest US insurer) is up 4,120% since 2000 vs. 340% gain for the S&P 500.
514
1,548
375
5,171
2,549,008
FDA Rejects Lilly’s Eczema Treatment Over Third-Party Manufacturing Issues | BioSpace biospace.com/article/fda-rej… #jobs
3
349
U.S. FDA declines to approve Eli Lilly's drug to treat eczema reuters.com/business/healthc…

U.S. FDA declines to approve Eli Lilly's drug to treat eczema

The U.S. Food and Drug Administration (FDA) has declined to approve Eli Lilly's drug to treat a type of skin disease due to certain findings during an inspection of a contract manufacturer, the...

reuters.com
2
204
Vaping increases risk of asthma in adolescents even without any tobacco smoking sciencedirect.com/science/ar…
3
11
2
14
2,741
With significant overlap between allergic rhinitis & chronic rhinosinusitis, it's important for primary care clinicians, allergists & otolaryngologists to appreciate various management approaches Excellent review re: surgical management of rhinosinusitis: loom.ly/QX7pOVc
1
7
14
1,262
Looking for a current, comprehensive, and fantastic review on allergic fungal sinusitis? We've got you covered in our September issue: loom.ly/qfxizCI
3
6
462
This recent editorial offers important thoughts for all of us to consider regarding the rising costs of prescription medication #MedTwitter loom.ly/bfXZLOY
3
4
340
Nasal spray alternative to EpiPen suffers setback as FDA seeks fresh study reuters.com/business/healthc…

Nasal spray alternative to EpiPen faces setback as FDA seeks fresh study

The U.S. health regulator has declined to approve a nasal spray that would have been the first needle-free emergency treatment for allergic reactions, a surprise decision that pushed shares of its...

reuters.com
1
108
Protecting children from poor air quality mottpoll.org/reports/protect… via @csmottpoll

Protecting children from poor air quality

3 in 4 parents are concerned about the impact of air quality problems on their child’s health. 2 in 3 parents report poor or unhealthy air quality in their area, most often related to wildfires....

mottpoll.org
1
144
Leading asthma groups tackle definition of clinical remission in treatment of asthma medicalxpress.com/news/2023-… via @medical_xpress

Leading asthma groups tackle definition of clinical remission in treatment of asthma

As an increasing number of improved asthma treatments are developed, a greater number of people with asthma are finding their symptoms under control. Their improved status raises an important...

medicalxpress.com
1
8
520
FDA Reviewers Say OTC Decongestant Doesn't Work medpagetoday.com/publichealt…

FDA Reviewers Say OTC Decongestant Doesn't Work

But they acknowledge that taking the only shelf-accessible product off the market raises issues

medpagetoday.com
1
1
3
321
firstwordpharma.com/story/57…
1
5
393
#Immunotherapy improved bronchial epithelial expression of IFN-beta and IFN-lambda while decreasing IL-33, said researchers at Bispebjerg Hospital. Also, Dr. Michael Blaiss of @wheezemd and Dr. Jay Lieberman of @UTHSCMedicine share their Perspectives. bit.ly/3OotyqG

Sublingual immunotherapy improves bronchial epithelial antiviral resistance

Sublingual immunotherapy for house dust mite allergic asthma improved bronchial epithelial antiviral resistance to viral infection, according to a study published in the American Journal of Respira...

healio.com
1
1
296
Moving to Threads @wheezemd1. Follow me there.
1
149
biospace.com/article/astraze…

AstraZeneca Halts Phase II Asthma Trial Due to Safety Findings in Toxicology Study

Pieris Pharmaceuticals announced partner AstraZeneca’s decision to discontinue clinical studies of elarekibep, an inhaled IL-4 receptor alpha inhibitor, based on a non-clinical toxicology study.

biospace.com
1
1
1
251
Alladapt looks to advance food allergy drug to Phase III firstwordpharma.com/story/57… via @fwpharma
2
3
349
Blueprint's Ayvakit gets FDA nod for indolent systemic mastocytosis firstwordpharma.com/story/57… via @fwpharma
1
216
Michael Blaiss, MD retweeted
STAT
@statnews17 May 2023
Medicare Advantage plans are using algorithms to cut off care for seniors in need. Read previous reporting from @bobjherman and @caseymross trib.al/9tuXcQQ

Denied by AI: How Medicare Advantage plans use algorithms to cut off care for seniors in need

A STAT investigation found artificial intelligence is driving Medicare Advantage denials to new heights, cutting off care for seniors.

statnews.com
1
5
1
5
4,344
‘Stunning’ change to United’s colonoscopy coverage roils physicians and patients statnews.com/2023/05/15/unit… via @statnews. Just when you think it can’t get any crazier.
1
159
Michael Blaiss, MD retweeted
Integrity CE, LLC@IntegrityCE12 May 2023
Direct consequences of poorly controlled AR/C include: 💤 Sleep loss leading in daytime fatigue ↘️ Decreased quality of life ➕ More View this pediatric allergic rhinitis activity w/ @wheezemd & Erin Tomlin, MD, FAAP to earn 🆓 #CME: bit.ly/3AjJBhy #MedEd #FOAMed
1
135

No more items